Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research Paper

COVID-19 pandemic: Effect on management of patients with breast cancer; single center retrospective cohort study

Mehwish Mooghal a, b, *, Rana Hassan Javaid a, b, Wajiha Khan c, Muhammad Muneeb c, Waseem Ahmad Khan a, b, Asrar Ahmad a, b, Lal Bux Barohi a, b, Kamran Rahim a, b, Hina Tahseen b, Amna Gul b

a Department of Surgery, PNS Shifa Hospital, Karachi, Pakistan
b Department of Surgery, Bahria University Medical and Dental College, Karachi, Pakistan
c Dow University of Health and Sciences, Karachi, Pakistan

1. Introduction

In December 2019, novel corona virus (SARS-COV-2) originated from Wuhan, Hubei province of China [1]. Since COVID 19 was declared as a pandemic by WHO on March 11, 2020; hospitals have opted to dispense maximum resources to critical COVID 19 affected patients; this strategy has affected both elective and semi elective procedures [2]. It has been observed that patients with chronic illnesses, especially cancer, are at greater risk to develop severe disease course among COVID-19 patients [3].

Breast cancer is the most prevalent cancer among female population and causes 15% of total cancer deaths in developed countries, making it the leading cause of mortality [4]. Pakistan has a (>5.2 times) higher incidence and (>2.8 times higher) mortality rate of breast cancer than the rest of Asia [5]. The late diagnosis of breast cancer is the main reason for a higher mortality rate in Pakistan. This roots from many different factors like lack of awareness about the disease, non-availability of adequate...
screening and diagnostic facilities and social taboos associated with breast related conditions [6]. The recent COVID 19 pandemic and the lockdown which immediately followed it in Pakistan, has added more burden to the above-mentioned challenges faced in cancer care. Furthermore, healthcare workforce is correspondingly insufficient in Pakistan (being a low-income region) to deal with the burden of cancer [6]. Keeping in view this scenario many hospitals in our region have started to triage the cases presenting to hospitals so that unwanted utilization of sources can be minimized, but this strategy and overall lockdown has led to delayed presentation of cancer cases to hospitals notably breast cancer cases.

The primary aim of this study was to determine how the COVID-19 pandemic has affected the presenting stage of breast cancer in our region and its effects on overall onco-surgical management of patients. We also hypothesized that COVID status can have significant impact on presentation, treatment initiation and definitive surgery. Our secondary aim was to correlate COVID status with delay time and its notable impact on overall upstaging of the breast cancer.

2. Methods

This single-centered retrospective cohort study was conducted at department of surgery of a public/private hospital in Karachi, Pakistan after obtaining permission from ethical review committee of hospital. The research registry number is NCT04929964. Patient’s data of all operated cases for suspicious lump breast (abnormal findings on ultrasound and mammogram, BIRAD III or above and abnormal FNAC results; C3 or above) from January 1st, 2020 to 30th June 2021, who presented to our hospital was retrieved on standard pre-designed questionnaire forms using old documents and phone calls by a single researcher to exclude observer bias. Informed consent was taken from participants before inclusion in the study. Patients were informed in brief about the reasons for conducting the study and its implications on future management of the disease. Out of these only following patients were included; females with diagnosed breast cancer on histopathological examination, age ≥20yrs, all stages of breast cancer, ASA I/II/III patients. Exclusion criteria was; patients who already had their surgery pre covid (December 2019), males, ASA IV/V patients.

Patient presentation time was calculated as the time interval between the appearance of the first symptoms of breast cancer (day 0) and the date of initial presentation to hospital by patient and consultation for breast symptoms. Time taken for start of treatment was calculated by counting number of days from the first presentation day to hospital until the date when definitive treatment for Carcinoma Breast was initiated (chemo/radio/surgery). Time duration for definitive surgery was counted from the day of first presentation to the hospital till the date surgery was conducted (modified radical mastectomy (MRM)/breast conserving surgery (BCS)/toilet mastectomy).

Presentation 'Delay' was defined as a patient reporting to the hospital for medical advice 30 after noticing the first possible symptoms of breast cancer while [7]. Time taken for start of treatment was calculated form time of first presentation to hospital (day 0) till the first day of start of definitive first treatment for breast cancer. We labelled delay in treatment if it was initiated later than 62 days (from day 0) [6].

The questionnaire inquired about the symptoms, date of presentation of the first symptoms, date of first reporting to hospital, reasons for the delayed presentation.

It was a non probability consecutive sampling technique. All patients who were admitted underwent pre anesthesia assessment, pre surgical optimization and COVID testing according to the hospital protocol. If the patient turned out COVID positive, their symptoms were noted and the COVID team (infectious disease department) was notified. The quarantine protocol at our hospital was complete isolation for 14 days with one PCR-negative report after completing quarantine, with no residual respiratory symptoms of cough, fever, and shortness of breath. This protocol was followed for all elective breast surgery patients admitted in the hospital. All COVID-positive patients underwent the same treatment protocol as non-COVID patients with regards to management of breast cancer. Patients with early breast cancer (up to stage 2A) underwent modified radical mastectomy/breast conservative surgery (therapeutic) first, followed by chemotherapy/radiotherapy, locally advanced cases (stage 2B and above) had neo-adjuvant treatment first followed by surgery (therapeutic), and advanced cases (stage 4/metastatic) underwent palliative treatment. All surgeries were carried out by a single team of general/plastic surgeons of our hospital. Post operative patients were taken care of in general wards/ICU/HDU according to the level of post operative care needed. Follow up of the patients was carried out by the same operating team to provide quality care assurance.

All the data obtained was analyzed using IBM SPSS version 23.0. Descriptive statistics like age were presented as range and means. Categorical data were analyzed using Fisher’s exact test and t-test was applied to numerical data. In all cases, a 95% confidence interval was used and p value ≤ 0.05 was considered significant. The work has been reported in the line with the STROCSS criteria [9].

3. Results

Eighty seven patients presented with a suspicious lump breast from January 2020 till June 2021. All patients were female, ranging from 25 to 71 years of age (mean 53 ± 5.45). On histo-pathological examination 18 (20.6%) patients had benign lesions, while 69 (79.3%) were diagnosed with breast cancer. Those who presented with a benign lump were excluded from the study. Sixty patients turned out to be COVID-positive on PCR testing. All COVID-positive patients underwent the same treatment protocol as non-COVID patients with regards to management of breast cancer.

Among them the patients whose stage remained the same, they underwent MRM (therapeutic intend) followed by adjuvant treatment. Out of the 9 patients who had their disease upstaged due to delay in treatment, 3 patients had their COVID positive status.

Eight patients presented to hospital for medical advice 30 after noticing the first possible symptoms of breast cancer while [7]. Time taken for start of treatment was calculated from time of first presentation to hospital (day 0) till the first day of start of definitive first treatment for breast cancer. We labelled delay in treatment if it was initiated later than 62 days (from day 0) [6].

The questionnaire inquired about the symptoms, date of presentation of the first symptoms, date of first reporting to hospital, reasons for the delayed presentation.

It was a non probability consecutive sampling technique. All patients who were admitted underwent pre anesthesia assessment, pre surgical optimization and COVID testing according to the hospital protocol. If the patient turned out COVID positive, their symptoms were noted and the COVID team (infectious disease department) was notified. The quarantine protocol at our hospital was complete isolation for 14 days with one PCR-negative report after completing quarantine, with no residual respiratory symptoms of cough, fever, and shortness of breath. This protocol was followed for all elective breast surgery patients admitted in the hospital. All COVID-positive patients underwent the same treatment protocol as non-COVID patients with regards to management of breast cancer. Patients with early breast cancer (up to stage 2A) underwent modified radical mastectomy/breast conservative surgery (therapeutic) first, followed by chemotherapy/radiotherapy, locally advanced cases (stage 2B and above) had neo-adjuvant treatment first followed by surgery (therapeutic), and advanced cases (stage 4/metastatic) underwent palliative treatment. All surgeries were carried out by a single team of general/plastic surgeons of our hospital. Post operative patients were taken care of in general wards/ICU/HDU according to the level of post operative care needed. Follow up of the patients was carried out by the same operating team to provide quality care assurance.

All the data obtained was analyzed using IBM SPSS version 23.0. Descriptive statistics like age were presented as range and means. Categorical data were analyzed using Fisher’s exact test and t-test was applied to numerical data. In all cases, a 95% confidence interval was used and p value ≤ 0.05 was considered significant. The work has been reported in the line with the STROCSS criteria [9].

3. Results

Eighty seven patients presented with a suspicious lump breast from January 2020 till June 2021. All patients were female, ranging from 25 to 71 years of age (mean 53 ± 5.45). On histo-pathological examination 18 (20.6%) patients had benign lesions, while 69 (79.3%) were diagnosed with breast cancer. Those who presented with a benign lump were excluded from the study. Sixty patients turned out to be COVID-positive on PCR testing. All COVID-positive patients underwent the same treatment protocol as non-COVID patients with regards to management of breast cancer.
adjuvant treatment. The other 3 patients had stage 2 A/B which was upstaged to 3 A/B after delay. They had neo-adjuvant followed by MRM (therapeutic). The course of treatment changed from MRM to toilet mastectomy (palliative) in three patients after upstaging of the disease from stage 3 → 4. However, a significant correlation was found between COVID positive status and disease upstaging, which is shown in Table 3.

4. Discussion

The Covid-19 pandemic which started in December 2019, is not over yet and at present it cannot be predicted when this is going to end as it depends on multiple factors like infectivity of a person, the isolation measures and lockdown status of affected countries, and emerging immunity [10]. The vaccination campaign is having an impact, albeit slowly, as with current vaccination pace in Pakistan it will take ages for the country to achieve herd immunity.

With the reallocation of the maximum resources by the hospital to the COVID-19 patient care in critical units, resource demanding diseases like breast cancer services have faced serious setbacks. We have tried to quantify what setbacks breast cancer care has taken in our hospital due to this pandemic. We have seen in our study that these patients present extremely late to the hospital due to a myriad of known and unknown reason.

On top of that sometimes they are just lost to follow up for indefinite periods even after the treatment has started. Although we tried to continue with the same treatment protocol for COVID negative and positive patients the patients with positive PCR had to be quarantined as per hospital policy in vogue, which may have contributed to upstaging of disease in a some of these patients.

We determined in our study that most of the patients 60 (87%) presented with advanced (stage 2b and above) of breast cancer. This is comparable to another research in Pakistan where 69.9% females reported in stage III and IV of Breast Cancer [11]. This presentation in advanced stage can be due to longer patient delays from noticing first symptom to presenting to a health care facility as explained in a meta-analysis by Richard et al. in which a positive relation was seen between patient delay and advanced stage of breast cancer at presentation [11,12]. In our study 45 (65.2%) patients reported late with majority (75%) of them presenting with a delay of 6 months or more, after noticing the initial symptoms. This is in congruence with another study conducted in northern Pakistan where 39% patients reported with a delay of 6 months [12]. Unlike what we expected due to the current situation engendered by COVID-19 pandemic, unawareness (30.4%) still outnumbered COVID lockdown (21.7%) as the main factor causing the delay, while 13% reported both

| Table 1 | Overall time duration of presentation, treatment, and surgery. |
|---|---|---|
| Time duration taken to present to hospital (from noticing first symptom) | Time duration for start of definitive treatment (from presentation to hospital) | Time duration from hospital presentation to surgery |
| Number of patients | 69 | 69 | 69 |
| Mean in days (SD) | 118.48 (±133.60) | 95.08 (±123.44) | 308.48 (±246.97) |
| Minimum | 0 | 13 | 20 |
| Maximum | 390 | 480 | 1020 |

| Table 2 | Overall delay with reasons and impact on stage of disease (n = 23). |
|---|---|---|
| Delay In Presentation | No | 24 | 34.8 |
| Yes | 45 | 65.2 |
| Reason of Delay | COVID lockdown | 15 | 21.7 |
| no delay seen | 24 | 34.8 |
| follow up loss and unawareness | 9 | 13 |
| unawareness | 21 | 30.4 |
| Treatment Delay | No | 42 | 60.8 |
| Yes | 27 | 39.1 |
| Upstaging | No | 48 | 69.6 |
| Yes | 21 | 30.4 |

| Table 3 | Time duration of presentation, initiation of treatment and definitive surgical management according to COVID status. |
|---|---|---|---|---|---|
| Group Statistics | COVID status | Number of patients | Mean | Std. Deviation | p-value | 95% Confidence Interval of the Difference |
| Duration of days for presentation to hospital | Neg | 57 | 119.74 | 145.15 | 0.92 | Lower | Upper |
| Positive | 12 | 112.5 | 66.52 | | | |
| Duration for definitive treatment in days | Neg | 57 | 101.26 | 133.82 | 0.61 | | |
| Positive | 12 | 65.75 | 53.96 | | | |
| Duration of days from hospital presentation to surgery | Neg | 57 | 340.95 | 255.67 | 0.18 | | |
| Positive | 12 | 154.25 | 129.17 | | | |
| Upstaging | Neg | 57 | 2.16 | 0.5 | 0.04 | | |
| Positive | 12 | 2.75 | 0.5 | | | |
reasons as the cause of delay. A few cases were lost to follow up due to not understanding the gravity of their disease and did not reported back on time for treatment continuation. Lack of awareness, peculiarly in developing countries, is highlighted as the key factor contributing to delayed presentation and mortality in many studies [13,14]. This plays a significant role in delayed presentation as it roots from illiteracy and inaccessibility of the proper education to understand symptoms of any disease [15–21]. Recently, Government of Pakistan has started awareness campaigns regarding Breast Cancer which we believe will have positive impact in near future.

Though our study does not focus on determining the incidence of COVID-19 among Breast Cancer patients, only a small number of breast cancer patients (17.4%) tested positive which indicates that the suggestion, that breast cancer patients are not at higher risk of COVID-19 than the general population by Vuagnat et al., may have notable footing [22]. Moreover, we found out that the COVID status itself doesn’t have the significant impact on delay in presentation, definitive treatment or surgery. Though, for those testing positive, we followed the quarantine protocol of 14 days isolation with one PCR negative report after completing quarantine but still it did not cause a noteworthy delay in time from presentation to treatment as we tried to avoid unnecessary treatment and surgical delay [23]. Interestingly, our study highlighted that COVID status does have significant impact on the upstaging of the breast cancer as our data emphasized that a notable number of COVID positive patient underwent upstaging. Plausible explanation may be factors like advanced tumor stage on presentation and high histopathological grade of tumor at presentation, combined with treatment delay (chemo/surgery) due to COVID quarantine [24,25]. Future research is needed to investigate that if corona virus itself can contribute in patho-physiology of upstaging.

The limitations of this work include a small number of patients from a single center. So, our results may not be generalizable. For this a multi-centric study with a large sample size needs to study the overall outcome of COVID-19 on breast cancer patients and disease progression among them. We also did not include histopathological correlation and response of different types of breast cancer to chemotherapy with disease upstaging and covid status. More research work is needed to find relation of disease upstaging with COVID status.

5. Conclusion

We found that covid-19 pandemic had no significant impact on delay in presentation, breast cancer management/treatment and disease upstaging as compared to figures available for our population before the pandemic. However, our study showed significant correlation between disease upstaging and COVID positive status of patients. These findings made us think to reconsider our protocols of breast cancer care management among Covid positive patients in this pandemic. Our results might help researchers in formulating new breast cancer management guidelines for patients in current or any anticipated future pandemic.

Ethical approval

Ethical review was given by ethical review committee of hospital (PNS Shifa Hospital Karachi), which has board of members and one person as Head. The number allotted to our research was ERC:43.

Funding

None to declare.

Author contribution

Dr Mehwish Mooghal: study design, main concept, data collections, data analysis, writing, reviewing.

Dr Rana Hassan Javaid: study design, concept, data analysis, writing, reviewing.

Wajihah Khan: design, concept, data analysis, writing, reviewing.

Muhammad Muneeb: design, concept, data analysis, writing, reviewing.

Dr Asrar Ahmad: design, concept, data analysis, writing, reviewing.

Dr Waseem Ahmad Khan: design, concept, data analysis, writing, reviewing.

Dr Lal Bux Brohi: design, concept, data analysis, writing, reviewing.

Dr Kamran Rahim: design, concept, data analysis, writing, reviewing.

Dr Hina Tahseen: design, concept, data analysis, writing, reviewing.

Dr Amna Gul: design, concept, data analysis, writing, reviewing.

Conflict of interest statement

None to declare.

Guarantor

Dr Mehwish Mooghal.

Dr Rana Hassan Javaid.

Research registration number

1. Name of the registry: ClinicalTrials.gov.
2. Unique Identifying number or registration ID: NCT04929964.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://clinicaltrials.gov/show/NCT04929964.

Disclaimer

Nil.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Acknowledgement

Nil.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ijso.2021.100386.

References

[1] Elghazawy H, Baklakj J, Zaghloul MS, Abusanad A, Hussein MM, Alorabi M, et al. Implementation of breast cancer continuum of care in low-And middle-income countries during the COVID-19 pandemic. Future Oncol 2020;16:2551–67.
[2] Rosenbaum L. Facing covid-19 in Italy — ethics, logistics, and therapeutics on the epidemic’s front line. N Engl J Med 2020;382(20):1873–5.
[3] Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020;35(5):1545–9.
[4] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca - Cancer J Clin 2018 Nov;68(6):394–424.
[5] Luzzati T, Parenti A, Rughi T. Economic growth and cancer incidence. Ecol econ, vol. 146. Elsevier; 2018. p. 381—96.

[6] Gulzar F, Akhtar MS, Sadiq R, Bashir S, Jamil S, Baig SM. Identifying the reasons for delayed presentation of Pakistani breast cancer patients at a tertiary care hospital [Internet]. Canc Manag Res 2019;11:1087—96 [cited 2021 Jan 4]. Available from: pmc/articles/PMC6357878/?report=abstract.

[7] Shamsi U, Khan S, Azami I, Usman S, Maqbool A, Gill T, et al. Patient delay in breast cancer diagnosis in two hospitals in Karachi, Pakistan: preventive and life-saving measures needed. JCO Global Oncol 2020 Sep;6:873—83.

[8] CANCER RESEARCH UK [homepage of CANCER RESEARCH UK] [cited 18 May 2021] Available form : URL : https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/access-to-treatment/waiting-times-after-diagnosis; 6 Jan 2020.

[9] Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G, for the STROCSS Group. The STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg 2019;72:156—65.

[10] Pruitt L, Mumuni T, Raikhel E, Ademola A, Ogundiran T, Adenipekun A, et al. Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Iladan, Nigeria. Global Publ Health 2015;10(3):331—44.

[11] Bish A, Ramirez A, Burgess C, Hunter M. Understanding why women delay in seeking help for breast cancer symptoms. J Psychosom Res 2005;58(4):321—6.

[12] McLachlan S, Mansell G, Sanders T, Yardley S, Windt D, Brundle L, et al. Symptom perceptions and help-seeking behaviour prior to lung and colorectal cancer diagnoses: a qualitative study. Fam Pract 2015;32(5):568—77.

[13] Ouasmani F, Hanchi Z, Haddou Rahou B, Bekkali R, Ahid S, Mesfoui A. Determinants of patient delay in seeking diagnosis and treatment among Moroccan women with cervical cancer. Obstet Gynecol Int 2016:9.

[14] Malik IA. Clinico-pathological features of breast cancer in Pakistan. J Pakistan Med Assoc 2002;52:100—4.

[15] Khan MA, Shahzad MF, Iqbal S. Presentation delay in breast cancer patients, identifying the barriers in North Pakistan. Asian Pac J Cancer Prev APJCP 2015;16(1):377—80.

[16] Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, et al. Breast cancer presentation and diagnostic delays in young women. Cancer 2014 Jan 1;120(1):20—5.

[17] Khan MA, Hanif S, Iqbal S, Shahzad MF, Shafique S, Khan MT. Presentation delay in breast cancer patients and its association with sociodemographic factors in North Pakistan. Chin J Canc Res 2015;27(3):288.

[18] Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335—7.

[19] Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011;260:119—28.

[20] Lee SK, Yang JH, Woo SY, Lee JE, Nam SJ. Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast. Br J Surg 2013;100:1756—63.